DOCSLIB.ORG

11B-Hydroxylase Deficiency, 36 17,20 Desmolase Deficiency, 36 17

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
11B-Hydroxylase Deficiency, 36 17,20 Desmolase Deficiency, 36 17 Index 11b-Hydroxylase deficiency, 36 American Society of Reproductive Medicine Classification, 17,20 Desmolase deficiency, 36 66–67 17-Hydroxylase deficiency, 158 Anaesthesia, 2–3 17b-Hydroxysteroid dehydrogenase type, 3, 130 Androgen Excess Society diagnostic criteria, 156 17b-OH-dehydrogenase deficiency, 36 Androgen insensitivity syndrome 21-Hydroxylase deficiency—(see also Congenital adrenal complete, 5, 44, 164–166 hyperplasia-classic), 35, 39, 42, 140, 160 diagnostic criteria, 165 3b-Hydroxysteroid hydrogenase deficiency, 35–36 imaging, 44–45, 165 46,XX Disorders of sex development, 36, 39, 42–43 mild, 164 5a-Reductase deficiency, 35–36, 46–47 partial, 44–45, 164–165 b-hCG level, 182, 199, 201–202, 206 Androgen receptor, 44 mutation, 44, 164 Anorexia nervosa, 148, 150 A Anosmia, 125 Abdominopelvic cyst (see Cyst—abdominopelvic) Anovulation, 147 Acromegaly, 137, 156 Anti-Müllerian hormone, 22, 33–34, 127, 130, 160 Addison disease (see Adrenal insufficiency) Assessment of skeletal maturity (see Bone age) Adenomyosis, 205 Autoimmune oophoritis, 148, 158, 160 Adenomyotic cyst, 205 Adnexa, 92 Adnexal B masses, 185 Balanced X chromosome translocations, 158 torsion (also see Ovarian Torsion), 185 Bartholins glands, 30 volume ratio, 175, 177, 190, 193 Beckwith-Wiedemann syndrome, 141, 161, 218 Adrenal Blepharophimosis-ptosis-epicanthus adenoma, 140–141, 161 inversus syndrome, 158 androgen-secreting tumour, 132, 156 Blood dyscrasia, 147 cerebriform morphology, 40 Body mass index, 16, 118, 134 carcinoma, 140–141, 161–162 Bone age insufficiency, 158, 159 automated analysis, 108 normal imaging appearances, 103, 106–107 Fels method, 105, 118 oestrogen-secreting tumour, 132–133 Greulich and Pyle, 105, 118 rest tumour, 42, 160 Tanner-Whitehouse methodologies, 105 Adrenarche, 117, 131 Bone mineral exaggerated, 131–132 content, 108 premature, 115, 117, 130 density, 109 Adrenocortical tumour, 116, 140, 161 Breast Adrenocorticotropic Hormone deficiency, 140 abscess, 233–234 Alphafetoprotein, 211 amastia, 233 Amenorrhoea aplasia, 232 clinical assessment, 149 asymmetry, 231–232 endocrine investigations, 149 athelia, 232 primary, 148, 151 clinical evaluation, 230 secondary, 148–149 cyst, 234–235 G. Mann et al. (eds.), Imaging of Gynecological Disorders in Infants and Children, Medical Radiology. 247 Diagnostic Imaging, DOI: 10.1007/978-3-540-85602-3, Ó Springer-Verlag Berlin Heidelberg 2012 248 Index B(cont.) atresia, 56 development, 117, 132, 149, 226–227 stenosis, 147, 149 embryology, 226 Cervicovaginal atresia, 68 fibroadenoma, 239–240 Cervix uterus fibrocystic disease, 236 anatomy, 84, 86 galactocele, 236 MRI appearances, 88–89 giant fibroadenoma, 240 ultrasound appearances, 86 haemangioma, 238 Chemotherapy, 119, 158 haematoma, 237 Choriocarcinoma, 201–202, 211 hypomastia, 233 Chromosomal sex, 22, 32 hypoplasia, 231–232 Classification lobule, 228 American Society of Reproductive Medicine, 66–67 lymphangioma, 237 clinico-embryological, 67 lactiferous ducts, 226 PVE, 41 lymphatic drainage, 228 Prader, 41 lymphoma, 242 Clear cell carcinoma, 221 macromastia, 233 Clinico-embryological Classification, 67 malignant masses, 241–242 Cliteromegally, 61–62 mamma aberrata, 230 Clitoris, 28–29 mammary duct ectasia, 236 Cloaca, 27, 35 mammary ridge, 226 Cloacal mammography, 228 malformation, 7, 51–52, 56–59, 70 management of solid mass, 238 membrane, 27–28, 35 metastases, 241 Colour Doppler, 6–7 milk lines, 226 Complete androgen insensitivity syndrome (see androgen nipple discharge, 243 insensitivity syndrome) phyllodes tumour, 240 Complete hydatiform mole, 174, 201 polymastia, 230 Computed Tomography polythelia, 230 bowel preparation, 15 postnatal development, 226 contrast medium, 14 primary carcinoma, 242 indications, 13 primary mammary bud, 226 scanning parameters, 13 pseudomamma, 230 Congenital adrenal hyperplasia retroareolar cyst, 235 classic, 35, 39, 116, 130, 132–133, 139–140, 161 phabdomyosarcoma, 242 lipoid, 160 secondary mammary bud, 226 non-classic, 39, 130–133, 139 secondary tumours, 243 virilising, 148 supernumerary tissue, 230 Congenital androgen insensitivity syndrome (see Androgen Tanner staging, 227 insensitivity syndrome) ultrasound, 228 Congenital disorders of glycosylation, 158 vascular malformation, 237 Constitutional delay in growth and puberty, 148 vascular supply, 228 Corpus albicans, 97 virginal hypertrophy, 233 Corpus luteum, 97, 100–101 Bulimia nervosa, 148 Corpus luteum cyst, 179–184 Cortical cord (see secondary sex cord) Craniopharyngioma, 116, 119, 135 C Cryptomenorrhoea, 147, 185 Canal of Nuck, 24, 30 Criteria cyst, 24, 61 Androgen Excess Society diagnostic, 156 hydrocele, 61 Rotterdam consensus, 156 Carcinoma Cryptomenorrhoea, 147, 185 adrenal, 140–141, 161–162 Cushing syndrome, 118, 130, 137, 140, 148, 156, 160 breast primary, 242 Cyst ovarian, 210 abdominopelvic, 52 Carney complex, 141 Bartholin duct, 61 Cell duplication, 52–53 granulosa, 34 Gartner duct, 61–62 Leydig, 33–34, 116, 138 hymenal, 61 Sertoli, 33, 129 Kobelt, 195 theca, 34 mesonephric, 61, 195 Cervical mesothelial, 195 Index 249 Müllerian, 61 Endocrinology of female reproductive tract neonatal ovarian (see Ovarian cyst—neonatal) childhood, 83 paramesonephric, 195 during puberty, 83 paratubal, 195 infancy, 82 paraurethral, 61 onset of puberty, 83 paraurethral, 182 Endodermal sinus tumour, 168, 210–211 peritoneal inclusion, 195 Endometrial polyp, 147 Skene duct, 61 Endometrioma, 182–184, 187, 196, 202–204 urothelial, 61 Endometriosis vaginal wall inclusion, 61 aetiology, 202 Wolffian, 195 imaging, 202–204 Cystography, 13 staging, 203 Endometritis, 147, 175, 198 Endometrium (also see menstrual cycle), 3, 13, 86, 97–99, D 102, 104 Daughter cyst sign, 52–53 Epitheliod site trophoblastic tumour, 174, 201 Defects in androgen biosynthesis (also see Androgen Epoophoron, 26, 29–30 insensitivity syndrome), 36, 43, 119, 127 External genitalia differentiation, 22 Defects in testis determination, 42, 130 Dehydroepiandrosterone, 83 Dehydroepiandrosterone sulphate, 83 F DeMorsier syndrome (see Septo-optic dysplasia) Fallopian tubes Denys-Drash syndrome, 39–40 anatomy, 92, 96 Dermoid cyst (also see Ovarian teratoma), 16, 182, 188–189 isolated torsion, 193 Development imaging, 92 fallopian tubes, 34 Fibroid uterus (see Uterine—leiomyoma) ovaries (also see gonadal differentiation), 3, 40, 46 Fitzhugh-Curtis syndrome, 198 cervix, 26, 35 Follicle stimulating hormone, 82, 117, 123 external genitalia, 28–29, 38 Follicle stimulating hormone deficiency, 117, 129, 132 fallopian tubes, 26 Foreign body (see Vaginal—foreign body) uterus, 26, 35 Fragile X Mental Retardation-1 gene, 160 vagina, 26, 28, 38 Fragile X permutations, 158 Differentiation Fundocervical ratio, 6, 97 external genitalia, 22 gonadal, 3, 22–24, 40, 46 Müllerian duct differentiation, 22–26 G sexual, 23 Galactorrhoea, 152, 243 DiGeorge syndrome, 158 Galactosaemia, 158 Disorders of sex development Gartner duct (see Cyst—Gartner duct) aetiology, 35 Gartner’s pseudocyst, 68 classification, 35 Genital outflow tract stenosis, 56 clinical assessment and management of delayed Genital prolapsed, 61 presentations, 37 Genital Renal Ear and Skeletal syndrome, 76 initial clinical assessment and management, 35 Genital ridge long term clinical management, 48–49 agenesis, 68 nomenclature, 32 hypoplasia, 68 radiological assessment, 35 Genital tubercle, 35, 41–42 Dominant (Graafian) follicle, 97, 103, 155 Genitography Double wall sign, 52–53, 63 contraindications, 13 Dual-energy X-ray absorptiometry, 109 indications, 11 Ductal differentiation, 22 technique, 12 Duplication cyst (see Cyst—duplication) Genotype Dysfunctional uterine bleeding, 147 Germ cell tumour, 54, 152, 210–214 Dysgerminoma, 165, 211, 214 Germinoma, 135–136 Dysmenorrhoea, 146–147, 176 Gestational trophoblastic neoplasia, 201 Gonad bipotential (see also Indifferent gonad), 33 E intraabdominal, 45 Eating disorders, 148 labial, 37, 63, 164–165 Ectopic pregnancy (see Pregnancy—ectopic gestation) streak, 38, 43, 129–130, 158–160 Empty sella syndrome, 148, 152 Gonadal 250 Index G(cont.) Hypogonadotropic hypogonadism, 119, 121, 125, 151 agenesis, 148 Hypogonadotropic hypogonadism—idiopathic, 151–152 differentiation, 24 Hypomenorrhoea, 147 dysgenesis, 119, 127, 129–130, 148, 158 Hypooestrogenism, 150 complete, 35–36, 46–47 Hypoparathyroidism, 158–159 partial, 33, 43 Hypophosphatemic rickets, 138 ridge, 22–23 Hypopituitarism sexual differentiation, 22–24 congenital, 47 Gonadoblastoma, 39, 127, 152, 165, 211 idiopathic, 119 Gonadotoxic drugs, 148 Hyposmia, 125 Gonadotropin, 82–84, 96 Hypothalamic Gonadotropin glioma, 119, 135 receptor gene mutations, 158 hamartoma, 116, 133–135, 151 releasing hormone, 83, 117 infiltration, 148 releasing hormone-releasing neurones, 116, 123 irradiation, 148 Gorlin Syndrome, 218 tumour, 148, 150–151 Granulosa cell, 34 Hypothalamic-pituitary-gonadal axis, 102, 117, 130, 149 Granulosa-theca cell tumour, 214 Hypothyroidism, 117–118, 120, 129–130, 139, 147, Growth hormone 152, 155, 159 deficiency, 120–121, 125–126 excess, 137 Growth spurt, 117, 125 I Gubernaculum, 24 Idiopathic Hypogonadotropic Hypogonadism Gynaecological tract obstruction, 51–52, 56–58, 78, 163, (see Hypogonadotropic Hypogonadism—Idiopathic) 185–186 Imperforate hymen, 16, 56, 61, 149, 162 Implantation, 97 Indifferent gonad, 22–23, 26, 33 H Infundibulopelvic ligament, 24–25, 93–94 Haemangioma, 169 Inguinal hernia, 45, 51, 53, 61–62, 164 Haematocolpos, 78, 163, 186 Inhibin, 97, 138 Haematometrocolpos, 163, 186 Interlabial mass, 56, 60–61 Haematosalpinx, 184, 194, 196, 201 Intermenstrual bleeding,
Load more

Recommended publications
  • Lymphocytic Hypophysitis Successfully Treated with Azathioprine
    1581 J Neurol Neurosurg Psychiatry: first published as 10.1136/jnnp.74.11.1581 on 14 November 2003. Downloaded from SHORT REPORT Lymphocytic hypophysitis successfully treated with azathioprine: first case report A Lecube, G Francisco, D Rodrı´guez, A Ortega, A Codina, C Herna´ndez, R Simo´ ............................................................................................................................... J Neurol Neurosurg Psychiatry 2003;74:1581–1583 is not well established, but corticosteroids have been An aggressive case of lymphocytic hypophysitis is described proposed as first line treatment.10–12 Trans-sphenoidal surgery which was successfully treated with azathioprine after failure should be undertaken in cases associated with progressive of corticosteroids. The patient, aged 53, had frontal head- mass effect, in those in whom radiographic or neurological ache, diplopia, and diabetes insipidus. Cranial magnetic deterioration is observed during treatment with corticoster- resonance imaging (MRI) showed an intrasellar and supra- oids, or when it is impossible to establish the diagnosis of sellar contrast enhancing mass with involvement of the left lymphocytic hypophysitis with sufficient certainty.25 cavernous sinus and an enlarged pituitary stalk. A putative We describe an unusually aggressive case of pseudotumor- diagnosis of lymphocytic hypophysitis was made and ous lymphocytic hypophysitis successfully treated with prednisone was prescribed. Symptoms improved but azathioprine. This treatment was applied empirically because recurred after the dose was reduced. Trans-sphenoidal of the failure of corticosteroids. To the best to our knowledge, surgery was attempted but the suprasellar portion of the this is the first case of lymphocytic hypophysitis in which mass could not be pulled through the pituitary fossa. such treatment has been attempted. The positive response to Histological examination confirmed the diagnosis of lympho- azathioprine suggests that further studies should be done to cytic hypophysitis.
    [Show full text]
  • Te2, Part Iii
    TERMINOLOGIA EMBRYOLOGICA Second Edition International Embryological Terminology FIPAT The Federative International Programme for Anatomical Terminology A programme of the International Federation of Associations of Anatomists (IFAA) TE2, PART III Contents Caput V: Organogenesis Chapter 5: Organogenesis (continued) Systema respiratorium Respiratory system Systema urinarium Urinary system Systemata genitalia Genital systems Coeloma Coelom Glandulae endocrinae Endocrine glands Systema cardiovasculare Cardiovascular system Systema lymphoideum Lymphoid system Bibliographic Reference Citation: FIPAT. Terminologia Embryologica. 2nd ed. FIPAT.library.dal.ca. Federative International Programme for Anatomical Terminology, February 2017 Published pending approval by the General Assembly at the next Congress of IFAA (2019) Creative Commons License: The publication of Terminologia Embryologica is under a Creative Commons Attribution-NoDerivatives 4.0 International (CC BY-ND 4.0) license The individual terms in this terminology are within the public domain. Statements about terms being part of this international standard terminology should use the above bibliographic reference to cite this terminology. The unaltered PDF files of this terminology may be freely copied and distributed by users. IFAA member societies are authorized to publish translations of this terminology. Authors of other works that might be considered derivative should write to the Chair of FIPAT for permission to publish a derivative work. Caput V: ORGANOGENESIS Chapter 5: ORGANOGENESIS
    [Show full text]
  • Müllerian Aplasia and Hyperandrogenism
    Müllerian aplasia and hyperandrogenism Description Müllerian aplasia and hyperandrogenism is a condition that affects the reproductive system in females. This condition is caused by abnormal development of the Müllerian ducts, which are structures in the embryo that develop into the uterus, fallopian tubes, cervix, and the upper part of the vagina. Individuals with Müllerian aplasia and hyperandrogenism typically have an underdeveloped or absent uterus and may also have abnormalities of other reproductive organs. Women with this condition have normal female external genitalia, and they develop breasts and pubic hair normally at puberty; however, they do not begin menstruation by age 16 (primary amenorrhea) and will likely never have a menstrual period. Affected women are unable to have children ( infertile). Women with Müllerian aplasia and hyperandrogenism have higher-than-normal levels of male sex hormones called androgens in their blood (hyperandrogenism), which can cause acne and excessive facial hair (facial hirsutism). Kidney abnormalities may be present in some affected individuals. Frequency Müllerian aplasia and hyperandrogenism is a very rare disorder; it has been identified in only a few individuals worldwide. Causes Mutations in the WNT4 gene cause Müllerian aplasia and hyperandrogenism. This gene belongs to a family of WNT genes that play critical roles in development before birth. The WNT4 gene provides instructions for producing a protein that is important for the formation of the female reproductive system, the kidneys, and several hormone- producing glands. During the development of the female reproductive system, the WNT4 protein regulates the formation of the Müllerian ducts. This protein is also involved in development of the ovaries, from before birth through adulthood, and is important for development and maintenance of egg cells (oocytes) in the ovaries.
    [Show full text]
  • Use of Inflated Foley Catheters to Prevent Early Empty Pelvis Complications Following Pelvic Exenteration
    ANTICANCER RESEARCH 35: 5543-5546 (2015) Use of Inflated Foley Catheters to Prevent Early Empty Pelvis Complications Following Pelvic Exenteration NICOLAE BACALBASA1, DANA TOMESCU2 and IRINA BALESCU3 1Carol Davila University of Medicine and Pharmacy, Bucharest, Romania; 2Fundeni Clinical Institute, Department of Anaethesia and Critical Care III, Bucharest, Romania; 3Ponderas Hospital, Bucharest, Romania Abstract. For most patients with bulky pelvic tumors, neoadjuvant chemo-irradiation is performed in order to pelvic exenteration remains the only curative option. diminish the local invasion and to transform the patient into Although initially reported as a palliative procedure, a candidate for a less extended resection. However, there nowadays it is rather performed with curative intent. Once are cases in which local invasion persists after neoadjuvant the resectional phase is ended, a large defect will remain at treatment and in which pelvic exenteration is needed. Since the level of the pelvic diaphragm, predisposing to severe Brunschwig reported it for the first time in 1948, this complications which are generically included under the surgical procedure has become the golden-standard for name of empty pelvis syndrome. It has been widely patients with locally invasive pelvic malignancies (3). demonstrated that this type of complication is associated Although the resectional phase has remained practically with severe mortality, even if the patient is free of any pelvic unchanged, the reconstructive phase has undergone multiple recurrence. We present the case of a 56-year-old patient improvements in order to improve the patient quality of submitted to total pelvic exenteration for locally invasive life. However, there are still cases in which a reconstruction previously chemo-irradiated cervical cancer who presented is not possible at the time of resection; in all such cases, a six months after surgery with a severe enteroperineal fistula.
    [Show full text]
  • Uterine Rupture During Subsequent
    ISSN: 2474-1353 Nishida et al. Int J Womens Health Wellness 2018, 4:070 DOI: 10.23937/2474-1353/1510070 Volume 4 | Issue 1 International Journal of Open Access Women’s Health and Wellness RESEARCH ARTICLE Uterine Rupture during Subsequent Pregnancy following Adeno- myomectomy - Report of Five Cases and Proposal for Prevention Masato Nishida1*, Yasuo Otsubo1, Yuko Arai1, Ryota Ichikawa1, Yuzuru Kondo2, Hiroya Itagaki1 and Miyako Sakanaka1 1Department of Obstetrics and Gynecology, National Hospital Organization, Kasumigaura Medical Center, Japan 2Department of Pathology, National Hospital Organization, Kasumigaura Medical Center, Tsuchiura, Japan *Corresponding author: Masato Nishida, Department of Obstetrics and Gynecology, National Hospital Organization, Kasumigaura Medical Center, 2-7-14 Shimotakatsu, Tsuchiura, Ibaraki, 300-8585, Japan, Check for Tel: +81-29-822-5050, Fax: +81-29-824-0494, E-mail: [email protected] updates Abstract taining the possibility of conception following surgery Purpose: The risk of uterine rupture is a major concern for [2,3]. Various perinatal complications are associated women who become pregnant after undergoing an adeno- with an adenomyomectomy [4], thus consensus for its myomectomy. The aim of this study was to investigate the indications among obstetricians has not been obtained. mechanism of uterine rupture and improve the surgical pro- Notably, uterine rupture is a lethal condition for both cedure used for prevention. mother and fetus [5]. Material and methods: Five patients who experienced uterine rupture during subsequent pregnancy after under- It is clinically important to investigate the mecha- going an adenomyomectomy performed with an open lapa- nism of uterine rupture in affected patients, and also rotomy were retrospectively investigated.
    [Show full text]
  • HYPOPITUITARISM YOUR QUESTIONS ANSWERED Contents
    PATIENT INFORMATION HYPOPITUITARISM YOUR QUESTIONS ANSWERED Contents What is hypopituitarism? What is hypopituitarism? 1 What causes hypopituitarism? 2 The pituitary gland is a small gland attached to the base of the brain. Hypopituitarism refers to loss of pituitary gland hormone production. The What are the symptoms and signs of hypopituitarism? 4 pituitary gland produces a variety of different hormones: 1. Adrenocorticotropic hormone (ACTH): controls production of How is hypopituitarism diagnosed? 6 the adrenal gland hormones cortisol and dehydroepiandrosterone (DHEA). What tests are necessary? 8 2. Thyroid-stimulating hormone (TSH): controls thyroid hormone production from the thyroid gland. How is hypopituitarism treated? 9 3. Luteinizing hormone (LH) and follicle-stimulating hormone (FSH): LH and FSH together control fertility in both sexes and What are the benefits of hormone treatment(s)? 12 the secretion of sex hormones (estrogen and progesterone from the ovaries in women and testosterone from the testes in men). What are the risks of hormone treatment(s)? 13 4. Growth hormone (GH): required for growth in childhood and has effects on the entire body throughout life. Is life-long treatment necessary and what precautions are necessary? 13 5. Prolactin (PRL): required for breast feeding. How is treatment followed? 14 6. Oxytocin: required during labor and delivery and for lactation and breast feeding. Is fertility possible if I have hypopituitarism? 15 7. Antidiuretic hormone (also known as vasopressin): helps maintain normal water Summary 15 balance. What do I need to do if I have a pituitary hormone deficiency? 16 Glossary inside back cover “Hypo” is Greek for “below normal” or “deficient” Hypopituitarism may involve the loss of one, several or all of the pituitary hormones.
    [Show full text]
  • Detail Report
    Supplemental Update Report CR Number: 2012319113 Implementation Date: 16-Jan-19 Related CR: 2012319113 MedDRA Change Requested Add a new SMQ Final Disposition Final Placement Code # Proposed SMQ Infusion related reactions Rejected After Suspension MSSO The proposal to add a new SMQ Infusion related reactions is not approved after suspension. The ICH Advisory Panel did approve this SMQ topic to go into the development phase and it Comment: underwent testing in three databases (two regulatory authorities and one company). However, there were numerous challenges encountered in testing and the consensus decision of the CIOMS SMQ Implementation Working Group was that the topic could not be developed to go into production as an SMQ. Most notably, in contrast to other SMQs, this query could not be tested using negative control compounds because it was not possible to identify suitable compounds administered via infusion that were not associated with some type of reaction. In addition, there is no internationally agreed definition of an infusion related reaction and the range of potential reactions associated with the large variety of compounds given by infusion is very broad and heterogenous. Testing was conducted on a set of around 500 terms, the majority of which was already included in Anaphylactic reaction (SMQ), Angioedema (SMQ), and Hypersensitivity (SMQ). It proved difficult to identify potential cases of infusion related reactions in post-marketing databases where the temporal relationship of the event to the infusion is typically not available. In clinical trial databases where this information is more easily available, users are encouraged to provide more specificity about the event, e.g., by reporting “Anaphylactic reaction” when it is known that this event is temporally associated with the infusion.
    [Show full text]
  • Huge Ovarian Sertoli-Leydig Cell Tumor- a Rare Presentation Mimicking Advanced Ovarian Carcinoma: a Clinical Diagnostic Pitfall
    International Journal of Health Sciences and Research Vol.10; Issue: 5; May 2020 Website: www.ijhsr.org Case Report ISSN: 2249-9571 Huge Ovarian Sertoli-Leydig Cell Tumor- A Rare Presentation Mimicking Advanced Ovarian Carcinoma: A Clinical Diagnostic Pitfall Ikeanyi M Eugene1, Udoye P Ezenwa2, Jeremiah Israel1 1Department of Obstetrics and Gynecology, Niger Delta University Teaching Hospital, Okolobiri Bayelsa State Nigeria 2Department of Pathology, Niger Delta University Teaching Hospital, Okolobiri Bayelsa State Nigeria Corresponding Author: Ikeanyi M Eugene ABSTRACT Sertoli-Leydig cell tumor is a very rare ovarian tumor constituting less than 0.5% of all primary ovarian tumors. It mostly occurs in second and third decades of life. This is a case report of a rare presentation of a huge ovarian Sertoli-Leydig cell tumor presenting like an advanced ovarian cancer in a 62 year old seven years postmenopausal para eight woman. At surgery was a left well encapsulated multilobulated ovarian tumour measuring 28 x28x14cm, weighing 6.2kg and histologically containing clusters of Leydig cells and solid cords of Sertoli cells of intermediate differentiation. The patient presented with a year history of progressive abdominal swelling and irregular vaginal bleeding. She had total abdominal hysterectomy and bilateral salpingo-oophorectomy. About a year on follow- up and stable. Keywords: Sertoli-Leydig cell, sex cord, stromal, ovarian, tumor, postmenopausal, neoplasm INTRODUCTION but rarely in any age. It can contain Ovarian Sertoli-Leydig cell tumor is heterologous elements and be functionally one of the categories of sex cord-stromal diverse. It contains testicular structures that tumors of ovary; defined by World Health secrete androgen with varying degrees of Organization (WHO) as groups of tumors virilization based on the quantity of secreted composed of granulosa cells, theca cells, androgen.
    [Show full text]
  • Use of Novel Serum Markers in Clinical Follow-Up of Sertoli-Leydig Cell Tumours
    CORE Metadata, citation and similar papers at core.ac.uk Article in press - uncorrected proof Provided by Open Access LMU Clin Chem Lab Med 2007;45(5):657–661 ᮊ 2007 by Walter de Gruyter • Berlin • New York. DOI 10.1515/CCLM.2007.120 2006/514 Short Communication Use of novel serum markers in clinical follow-up of Sertoli-Leydig cell tumours Miriam Lenhard1,*, Caroline Kuemper1, Nina Keywords: ovarian malignancy; Sertoli-Leydig cell Ditsch1, Joachim Diebold2, Petra Stieber3, tumour; serum marker; sex-cord stromal tumour. Klaus Friese1 and Alexander Burges1 1 Department of Obstetrics and Gynaecology, Sertoli-Leydig cell tumours are classified as sex-cord Campus Grosshadern, Ludwig-Maximilians- stromal tumours. They account for only 0.2% of University, Munich, Germany malignant ovarian tumours and are often found uni- 2 Department of Pathology, Ludwig-Maximilians- laterally (1). Synonyms in the literature are arrheno- University, Munich, Germany blastoma, androblastoma and gonadal stromal 3 Department of Clinical Chemistry, Ludwig- tumour of the android type. Most of these tumours Maximilians-University, Munich, Germany are described in young adults and less than 10% occur prior to menarche or after menopause (2). Two- thirds of all patients are diagnosed with this rare dis- Abstract ease due to the tumour’s hormone production (3). A 41-year-old patient (IV gravida, IV para) presented Background: Sertoli-Leydig cell tumours of the ovary with dyspnoea, enlarged abdominal girth and mela- account for only 0.2% of malignant ovarian tumours. ena. On physical examination, the abdomen was dis- Two-thirds of all patients become apparent due to the tended with a fluid wave.
    [Show full text]
  • Germ Cells …… Do Not Appear …… Until the Sixth Week of Development
    Reproductive System Session 1 Origin of the Sexes Lecture 1 Development of Male and Female Reproductive System 1 The genital system LANGMAN”S Medical Embryology Indifferent Embryo • Between week 1 and 6, female and male embryos are phenotypically indistinguishable, even though the genotype (XX or XY) of the embryo is established at fertilization. • By week 12, some female and male characteristics of the external genitalia can be recognized. • By week 20, phenotypic differentiation is complete. 4 Indifferent Embryo • The indifferent gonads develop in a longitudinal elevation or ridge of intermediate mesoderm called the urogenital ridge ❑ Initially…. gonads (as a pair of longitudinal ridges, the genital or gonadal ridges). ❑ Epithelium + Mesenchyme. ❑ Germ cells …… do not appear …… until the sixth week of development. • Primordial germ cells arise from the lining cells in the wall of the yolk sac at weeks 3-4. • At week 4-6, primordial germ cells migrate into the indifferent gonad. ➢ Male germ cells will colonise the medullary region and the cortex region will atrophy. ➢ Female germ cells will colonise the cortex of the primordial gonad so the medullary cords do not develop. 5 6 The genital system 7 8 • Phenotypic differentiation is determined by the SRY gene (sex determining region on Y). • which is located on the short arm of the Y chromosome. The Sry gene encodes for a protein called testes- determining factor (TDF). 1. As the indifferent gonad develops into the testes, Leydig cells and Sertoli cells differentiate to produce Testosterone and Mullerian-inhibiting factor (MIF), respectively. 3. In the presence of TDF, testosterone, and MIF, the indifferent embryo will be directed to a male phenotype.
    [Show full text]
  • Genetic Disorders in Premature Ovarian Failure
    Human Reproduction Update, Vol.8, No.4 pp. 483±491, 2002 Genetic disorders in premature ovarian failure T.Laml1,3, O.Preyer1, W.Umek1, M.HengstschlaÈger2 and E.Hanzal1 University of Vienna Medical School, Department of Obstetrics and Gynaecology, 1Division of Gynaecology and 2Division of Prenatal Diagnosis and Therapy, Waehringer Guertel 18-20, A-1090 Vienna, Austria 3To whom correspondence should be addressed. E-mail: [email protected] This review presents the genetic disorders associated with premature ovarian failure (POF), obtained by Medline, the Cochrane Library and hand searches of pertinent references of English literature on POF and genetic determinants cited between the year 1966 and February 2002. X monosomy or X deletions and translocations are known to be responsible for POF. Turner's syndrome, as a phenotype associated with complete or partial monosomy X, is linked to ovarian failure. Among heterozygous carriers of the fragile X mutation, POF was noted as an unexpected phenotype in the early 1990s. Autosomal disorders such as mutations of the phosphomannomutase 2 (PMM2) gene, the galactose-1-phosphate uridyltransferase (GALT) gene, the FSH receptor (FSHR) gene, chromosome 3q containing the Blepharophimosis gene and the autoimmune regulator (AIRE) gene, responsible for polyendocrinopathy-candidiasis-ectodermal dystrophy, have been identi®ed in patients with POF. In conclusion, the relationship between genetic disorders and POF is clearly demonstrated in this review. Therefore, in the case of families affected by POF a thorough screening, including cytogenetic analysis, should be performed. Key words: autosomal disorders/FSH receptor/inhibin/premature ovarian failure/X chromosome abnormalities TABLE OF CONTENTS diagnosis requires histological examination of a full-thickness ovarian biopsy (Metha et al., 1992; Olivar, 1996).
    [Show full text]
  • Diagnosis of Abnormalities in Gonadal Development BERNARD GONDOS, M.D
    ANNALS OF CLINICAL AND LABORATORY SCIENCE, Vol. 12, No. 4 Copyright © 1982, Institute for Clinical Science, Inc. Diagnosis of Abnormalities in Gonadal Development BERNARD GONDOS, M.D. Department of Pathology, University of Connecticut, Farmington, CT 06032 ABSTRACT The role of the clinical laboratory in the diagnosis of abnormalities in gonadal development is reviewed, beginning with a description of the normal differentiation of the ovary and testis and the major types of disorders encountered. The conditions are classified as resulting from abnormal go­ nadal differentiation, defective endocrine function or excessive endocrine activity. Germ cell neoplasms are also reviewed. Laboratory procedures utilized in evaluation of gonadal abnormalities include cytogenetic, hor­ monal, and histopathologic studies. Standard procedures are described as well as newer methods which have undergone increasing use in recent years and other specialized procedures which are under investigation for possible clinical application. Introduction tors may all play a role in the development of structural and functional abnormalities The role of the laboratory in the diagno­ of gonadal differentiation. As a result, sis of abnormalities in gonadal develop­ classifications of intersex disorders and ment is particularly important. Because of abnormalities of hormone production are the many varieties of such disorders and often confusing. their complex pathogenesis, the types of The present report reviews the labora­ laboratory tests utilized are quite varied. tory diagnosis of disorders of gonadal de­ The applications and significance of these velopment, beginning with a consider­ tests should be clearly understood, since ation of normal gonadal differentiation proper utilization and evaluation may be and a brief summary of the main categor­ critical in determining gender role assign­ ies of abnormalities.
    [Show full text]